Last reviewed · How we verify

NCT05065775: INDEX

Bioavailability of Intranasal Dexmedetomidine

Completed Phase 4 Last updated 17 May 2022
What this trial tests

Phase 4 trial testing Dexmedetomidine in Pharmacokinetics in 30 participants. Completed in 10 May 2022.

Timeline
1 November 2021
Primary endpoint
31 December 2021
10 May 2022

Quick facts

Lead sponsorTurku University Hospital
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment30
Start date1 November 2021
Primary completion31 December 2021
Estimated completion10 May 2022
Sites1 location across Finland

Drugs / interventions tested

Conditions studied

Sponsor

Turku University Hospital

Who can join

Adults 35 to 85, any sex, with Pharmacokinetics or Arthritis Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim of this study is to characterize the pharmacokinetics of dexmedetomidine in supine, anesthetized adult patients after intranasal dosing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

Other recruiting trials for Pharmacokinetics

Currently open trials in the same condition.

Other Turku University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05065775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing